Takeda Pharmaceutical (TAK) Asset Writedowns and Impairment (2018 - 2026)

Takeda Pharmaceutical's Asset Writedowns and Impairment history runs 9 years deep, the most recent figure standing at $324.7 million for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment fell 27.47% year-over-year to $324.7 million in Q1 2026; TTM through Mar 2026 was $966.1 million, a 38.73% increase from a year earlier, with the FY2026 full-year figure at $968.0 million, up 38.42% from the prior year.
• Asset Writedowns and Impairment improved to $324.7 million in Q1 2026 per TAK's latest filing, from $49.7 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $823.1 million in Q3 2023 and bottomed at $14.2 million in Q4 2024.
• The 5-year median for Asset Writedowns and Impairment is $110.1 million (2022), against an average of $207.2 million.
• Across the five-year window, Asset Writedowns and Impairment soared 22639.3% in 2022 and slumped 91.8% in 2024, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $42.6 million in 2022, then gained by 20.33% to $51.3 million in 2023, then sank by 72.26% to $14.2 million in 2024, then soared by 249.41% to $49.7 million in 2025, then surged by 553.52% to $324.7 million in 2026.
• Per Business Quant, the three latest TAK Asset Writedowns and Impairment figures stand at $324.7 million (Q1 2026), $49.7 million (Q4 2025), and $575.4 million (Q3 2025).